Cell culture media specialist Irvine Scientific has introduced PRIME-XV® NK Cell CDM as the first commercially available chemically-defined (CDM), animal component-free (ACF) medium for the ex-vivo expansion of NK cells while preserving cell potency and functionality.
Current approaches to immunotherapy focus on harnessing the power of the body’s immune system to treat tumours with cell therapiesand NK cells represent one of the promising therapies as they have the potential to recognize and kill cancer cells. Studies have shown that NK cells possess the ability to identify certain tumour cells or virus-infected cells and destroy them by injecting cell-degrading proteins into the malignant cells. However, NK cells are not naturally abundant in vivo, which presents a significant obstacle to their use in NK-mediated therapies and, therefore, the challenge is to produce sufficient numbers of cells that are cytotoxic towards cancer cells ex vivo to produce effective therapies.
A number of protocols have been developed to generate potent NK cells in sufficient numbers, but many popular methods present challenges for developing clinical applications due to their use of animal-derived components, such as serum and feeder cells. Co-culture systems with feeder cells are highly complex and variable, and there are legitimate concerns about undesirable components or genetic material transferring to the therapeutic cells as a consequence of the process. PRIME-XV® NK Cell CDM is the first commercially-available medium formulated to address this issue.
Designed for use in NK cell-based immunotherapy research and translational applications, this new medium delivers strong cell growth while also maintaining NK cell potency and functionality without the need for serum supplementation in either the presence or absence of feeder cells. The innovative formula offers researchers the option of avoiding many of the disadvantages associated with the use of feeder cells while maintaining the characteristic morphology and cytotoxicity of NK cells.
For further information about Irvine Scientific visit www.irvinesci.com
- Leading cell culture media company changes name to FUJIFILM Irvine Scientific, Inc
- Irvine Scientific now offers Falcon IVF products in the US
- JXTG Energy sells Irvine Scientific to FujiFilm
- Irvine Scientific increases cell culture dry powder media production capacity
- Irvine Scientific opens new R&D centre in Orange County, California
- Irvine Scientific introduces new xeno-free hematopoietic progenitor cell culture medium
- Charles River Laboratories expands oncology business
- Irvine Scientific develops novel bioassay for IVF components and media
- Irvine Scientific introduces animal-component-free T-cell culture medium for immunotherapy applications
Latest from Tom Mulligan
- SGS’s first malaria human challenge trial will take place in Belgium this month
- TC BioPharm creates allogeneic cell banks for CAR-T cancer therapy products
- Horizon Discovery extends CRISPR Screening Service to primary human T cells
- TrakCel and The Quick Life Science Group partner on supply chain IT solution for cell and gene therapies
- Almac Group extends personalised cancer vaccine production facilities
- Cobra Biologics appoints Dr Darrell Sleep as Director of Innovation
- Phico Therapeutics appoints financial director and two non-executive directors
- Evonetix appoints Stephanie Brooking as Head of Product Management
- Bio-Rad publishes new findings on generation and characterisation of drug-target-complex-specific antibodies
- Expedeon licenses Lightning-Link rapid biotinylation technology to Cell Guidance Systems